MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer

Nuo Yang, Sippy Kaur, Stefano Volinia, Joel Greshock, Heini Lassus, Kosei Hasegawa, Shun Liang, Arto Leminen, Shan Deng, Lori Smith, Cameron N. Johnstone, Xian-Ming Chen, Chang Gong Liu, Qihong Huang, Dionyssios Katsaros, George Adrian Calin, Barbara L. Weber, Ralf Bützow, Carlo M. Croce, George Coukos & 1 others Lin Zhang

Research output: Contribution to journalArticle

289 Citations (Scopus)

Abstract

MicroRNAs (miRNA) are approximately 22-nucleotide noncoding RNAs that negatively regulate protein-coding gene expression in a sequence-specific manner via translational inhibition or mRNA degradation. Our recent studies showed that miRNAs exhibit genomic alterations at a high frequency and their expression is remarkably deregulated in ovarian cancer, strongly suggesting that miRNAs are involved in the initiation and progression of this disease. In the present study, we performed miRNA microarray to identify the miRNAs associated with chemotherapy response in ovarian cancer and found that let-7i expression was significantly reduced in chemotherapy-resistant patients (n = 69, P = 0.003). This result was further validated by stem-loop real-time reverse transcription-PCR (n = 62, P = 0.015). Both loss-of-function (by synthetic let-7i inhibitor) and gain-of-function (by retroviral overexpression of let-7i) studies showed that reduced let-7i expression significantly increased the resistance of ovarian and breast cancer cells to the chemotherapy drug, cis-platinum. Finally, using miRNA microarray, we found that decreased let-7i expression was significantly associated with the shorter progression-free survival of patients with late-stage ovarian cancer (n = 72, P = 0.042). This finding was further validated in the same sample set by stem-loop real-time reverse transcription-PCR (n = 62, P = 0.001) and in an independent sample set by in situ hybridization (n = 53, P = 0.049). Taken together, our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer.

Original languageEnglish
Pages (from-to)10307-10314
Number of pages8
JournalCancer Research
Volume68
Issue number24
DOIs
StatePublished - Dec 15 2008

Fingerprint

MicroRNAs
Ovarian Neoplasms
Biomarkers
Drug Therapy
Reverse Transcription
Therapeutics
Polymerase Chain Reaction
Untranslated RNA
RNA Stability
Platinum
Cisplatin
Disease-Free Survival
In Situ Hybridization
Disease Progression
Ovarian epithelial cancer
Nucleotides
Breast Neoplasms
Gene Expression
Survival
Pharmaceutical Preparations

All Science Journal Classification (ASJC) codes

  • Cancer Research
  • Oncology

Cite this

Yang, N., Kaur, S., Volinia, S., Greshock, J., Lassus, H., Hasegawa, K., ... Zhang, L. (2008). MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. Cancer Research, 68(24), 10307-10314. https://doi.org/10.1158/0008-5472.CAN-08-1954

MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. / Yang, Nuo; Kaur, Sippy; Volinia, Stefano; Greshock, Joel; Lassus, Heini; Hasegawa, Kosei; Liang, Shun; Leminen, Arto; Deng, Shan; Smith, Lori; Johnstone, Cameron N.; Chen, Xian-Ming; Liu, Chang Gong; Huang, Qihong; Katsaros, Dionyssios; Calin, George Adrian; Weber, Barbara L.; Bützow, Ralf; Croce, Carlo M.; Coukos, George; Zhang, Lin.

In: Cancer Research, Vol. 68, No. 24, 15.12.2008, p. 10307-10314.

Research output: Contribution to journalArticle

Yang, N, Kaur, S, Volinia, S, Greshock, J, Lassus, H, Hasegawa, K, Liang, S, Leminen, A, Deng, S, Smith, L, Johnstone, CN, Chen, X-M, Liu, CG, Huang, Q, Katsaros, D, Calin, GA, Weber, BL, Bützow, R, Croce, CM, Coukos, G & Zhang, L 2008, 'MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer', Cancer Research, vol. 68, no. 24, pp. 10307-10314. https://doi.org/10.1158/0008-5472.CAN-08-1954
Yang, Nuo ; Kaur, Sippy ; Volinia, Stefano ; Greshock, Joel ; Lassus, Heini ; Hasegawa, Kosei ; Liang, Shun ; Leminen, Arto ; Deng, Shan ; Smith, Lori ; Johnstone, Cameron N. ; Chen, Xian-Ming ; Liu, Chang Gong ; Huang, Qihong ; Katsaros, Dionyssios ; Calin, George Adrian ; Weber, Barbara L. ; Bützow, Ralf ; Croce, Carlo M. ; Coukos, George ; Zhang, Lin. / MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. In: Cancer Research. 2008 ; Vol. 68, No. 24. pp. 10307-10314.
@article{ed68131aa68c468fa286b437b77bba20,
title = "MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer",
abstract = "MicroRNAs (miRNA) are approximately 22-nucleotide noncoding RNAs that negatively regulate protein-coding gene expression in a sequence-specific manner via translational inhibition or mRNA degradation. Our recent studies showed that miRNAs exhibit genomic alterations at a high frequency and their expression is remarkably deregulated in ovarian cancer, strongly suggesting that miRNAs are involved in the initiation and progression of this disease. In the present study, we performed miRNA microarray to identify the miRNAs associated with chemotherapy response in ovarian cancer and found that let-7i expression was significantly reduced in chemotherapy-resistant patients (n = 69, P = 0.003). This result was further validated by stem-loop real-time reverse transcription-PCR (n = 62, P = 0.015). Both loss-of-function (by synthetic let-7i inhibitor) and gain-of-function (by retroviral overexpression of let-7i) studies showed that reduced let-7i expression significantly increased the resistance of ovarian and breast cancer cells to the chemotherapy drug, cis-platinum. Finally, using miRNA microarray, we found that decreased let-7i expression was significantly associated with the shorter progression-free survival of patients with late-stage ovarian cancer (n = 72, P = 0.042). This finding was further validated in the same sample set by stem-loop real-time reverse transcription-PCR (n = 62, P = 0.001) and in an independent sample set by in situ hybridization (n = 53, P = 0.049). Taken together, our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer.",
author = "Nuo Yang and Sippy Kaur and Stefano Volinia and Joel Greshock and Heini Lassus and Kosei Hasegawa and Shun Liang and Arto Leminen and Shan Deng and Lori Smith and Johnstone, {Cameron N.} and Xian-Ming Chen and Liu, {Chang Gong} and Qihong Huang and Dionyssios Katsaros and Calin, {George Adrian} and Weber, {Barbara L.} and Ralf B{\"u}tzow and Croce, {Carlo M.} and George Coukos and Lin Zhang",
year = "2008",
month = "12",
day = "15",
doi = "10.1158/0008-5472.CAN-08-1954",
language = "English",
volume = "68",
pages = "10307--10314",
journal = "Journal of Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "24",

}

TY - JOUR

T1 - MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer

AU - Yang, Nuo

AU - Kaur, Sippy

AU - Volinia, Stefano

AU - Greshock, Joel

AU - Lassus, Heini

AU - Hasegawa, Kosei

AU - Liang, Shun

AU - Leminen, Arto

AU - Deng, Shan

AU - Smith, Lori

AU - Johnstone, Cameron N.

AU - Chen, Xian-Ming

AU - Liu, Chang Gong

AU - Huang, Qihong

AU - Katsaros, Dionyssios

AU - Calin, George Adrian

AU - Weber, Barbara L.

AU - Bützow, Ralf

AU - Croce, Carlo M.

AU - Coukos, George

AU - Zhang, Lin

PY - 2008/12/15

Y1 - 2008/12/15

N2 - MicroRNAs (miRNA) are approximately 22-nucleotide noncoding RNAs that negatively regulate protein-coding gene expression in a sequence-specific manner via translational inhibition or mRNA degradation. Our recent studies showed that miRNAs exhibit genomic alterations at a high frequency and their expression is remarkably deregulated in ovarian cancer, strongly suggesting that miRNAs are involved in the initiation and progression of this disease. In the present study, we performed miRNA microarray to identify the miRNAs associated with chemotherapy response in ovarian cancer and found that let-7i expression was significantly reduced in chemotherapy-resistant patients (n = 69, P = 0.003). This result was further validated by stem-loop real-time reverse transcription-PCR (n = 62, P = 0.015). Both loss-of-function (by synthetic let-7i inhibitor) and gain-of-function (by retroviral overexpression of let-7i) studies showed that reduced let-7i expression significantly increased the resistance of ovarian and breast cancer cells to the chemotherapy drug, cis-platinum. Finally, using miRNA microarray, we found that decreased let-7i expression was significantly associated with the shorter progression-free survival of patients with late-stage ovarian cancer (n = 72, P = 0.042). This finding was further validated in the same sample set by stem-loop real-time reverse transcription-PCR (n = 62, P = 0.001) and in an independent sample set by in situ hybridization (n = 53, P = 0.049). Taken together, our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer.

AB - MicroRNAs (miRNA) are approximately 22-nucleotide noncoding RNAs that negatively regulate protein-coding gene expression in a sequence-specific manner via translational inhibition or mRNA degradation. Our recent studies showed that miRNAs exhibit genomic alterations at a high frequency and their expression is remarkably deregulated in ovarian cancer, strongly suggesting that miRNAs are involved in the initiation and progression of this disease. In the present study, we performed miRNA microarray to identify the miRNAs associated with chemotherapy response in ovarian cancer and found that let-7i expression was significantly reduced in chemotherapy-resistant patients (n = 69, P = 0.003). This result was further validated by stem-loop real-time reverse transcription-PCR (n = 62, P = 0.015). Both loss-of-function (by synthetic let-7i inhibitor) and gain-of-function (by retroviral overexpression of let-7i) studies showed that reduced let-7i expression significantly increased the resistance of ovarian and breast cancer cells to the chemotherapy drug, cis-platinum. Finally, using miRNA microarray, we found that decreased let-7i expression was significantly associated with the shorter progression-free survival of patients with late-stage ovarian cancer (n = 72, P = 0.042). This finding was further validated in the same sample set by stem-loop real-time reverse transcription-PCR (n = 62, P = 0.001) and in an independent sample set by in situ hybridization (n = 53, P = 0.049). Taken together, our results strongly suggest that let-7i might be used as a therapeutic target to modulate platinum-based chemotherapy and as a biomarker to predict chemotherapy response and survival in patients with ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=57749105325&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=57749105325&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-08-1954

DO - 10.1158/0008-5472.CAN-08-1954

M3 - Article

VL - 68

SP - 10307

EP - 10314

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0008-5472

IS - 24

ER -